RU2005110062A - Дигидропиридиновые соединения, обладающие одновременной способностью к блокированию кальциевых каналов l-типа и к ингибированию активности фосфодиэстеразы типа 3 - Google Patents
Дигидропиридиновые соединения, обладающие одновременной способностью к блокированию кальциевых каналов l-типа и к ингибированию активности фосфодиэстеразы типа 3 Download PDFInfo
- Publication number
- RU2005110062A RU2005110062A RU2005110062/04A RU2005110062A RU2005110062A RU 2005110062 A RU2005110062 A RU 2005110062A RU 2005110062/04 A RU2005110062/04 A RU 2005110062/04A RU 2005110062 A RU2005110062 A RU 2005110062A RU 2005110062 A RU2005110062 A RU 2005110062A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- optionally substituted
- methyl
- Prior art date
Links
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 title 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 73
- 125000003342 alkenyl group Chemical group 0.000 claims 44
- 125000000304 alkynyl group Chemical group 0.000 claims 44
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 20
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 20
- 125000004450 alkenylene group Chemical group 0.000 claims 18
- 125000004419 alkynylene group Chemical group 0.000 claims 18
- 125000002947 alkylene group Chemical group 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 206010019280 Heart failures Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 6
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 230000006793 arrhythmia Effects 0.000 claims 3
- 230000004094 calcium homeostasis Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- -1 trifluoromethylphenyl Chemical group 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- KOHMLUDLOFJRBM-UHFFFAOYSA-N 3-o-ethyl 5-o-methyl 2-[2-[[2-[2-chloro-4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetyl]amino]ethoxymethyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound N1C(C)=C(C(=O)OC)C(C=2C(=CC=CC=2)Cl)C(C(=O)OCC)=C1COCCNC(=O)COC(C(=C1)Cl)=CC=C1C1=NNC(=O)CC1 KOHMLUDLOFJRBM-UHFFFAOYSA-N 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- IEWHOLAJSCSUMW-UHFFFAOYSA-N dimethyl 2-[2-[[2-[2-chloro-4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetyl]amino]ethoxymethyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C=1C(C=2C(=CC=CC=2)Cl)C(C(=O)OC)=C(C)NC=1COCCNC(=O)COC(C(=C1)Cl)=CC=C1C1=NNC(=O)CC1 IEWHOLAJSCSUMW-UHFFFAOYSA-N 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- OVWHHXGHCGYQOL-UHFFFAOYSA-N methyl 4-(2-chlorophenyl)-2,6-dimethyl-5-[2-[[2-[4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetyl]amino]ethylcarbamoyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)NCCNC(=O)COC=2C=CC(=CC=2)C=2CCC(=O)NN=2)C1C1=CC=CC=C1Cl OVWHHXGHCGYQOL-UHFFFAOYSA-N 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 0 CC1=C(*)NC(*I)=C(*)C1I* Chemical compound CC1=C(*)NC(*I)=C(*)C1I* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41625402P | 2002-10-07 | 2002-10-07 | |
| US60/416,254 | 2002-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005110062A true RU2005110062A (ru) | 2006-01-10 |
Family
ID=32093831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005110062/04A RU2005110062A (ru) | 2002-10-07 | 2003-10-07 | Дигидропиридиновые соединения, обладающие одновременной способностью к блокированию кальциевых каналов l-типа и к ингибированию активности фосфодиэстеразы типа 3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7098211B2 (https=) |
| EP (1) | EP1554267A1 (https=) |
| JP (1) | JP2006504738A (https=) |
| KR (1) | KR20050070036A (https=) |
| CN (1) | CN1720243A (https=) |
| AU (1) | AU2003275450A1 (https=) |
| BR (1) | BR0315103A (https=) |
| CA (1) | CA2501534A1 (https=) |
| MX (1) | MXPA05003640A (https=) |
| NO (1) | NO20052169L (https=) |
| PL (1) | PL376405A1 (https=) |
| RU (1) | RU2005110062A (https=) |
| WO (1) | WO2004033444A1 (https=) |
| ZA (1) | ZA200502711B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094806B2 (en) * | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| WO2005016885A2 (en) * | 2003-08-14 | 2005-02-24 | Artesian Therapeutics, Inc. | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE |
| WO2005035505A2 (en) * | 2003-09-30 | 2005-04-21 | Artesian Therapeutics, Inc. | Compounds with phosphodiesterase inhibiting and calcium channel blocking activities |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| KR20070087602A (ko) * | 2004-12-13 | 2007-08-28 | 아이알엠 엘엘씨 | 화합물 및 스테로이드성 수용체 및 칼슘 채널 활성의조절제로서의 조성물 |
| NL1028564C2 (nl) * | 2005-03-17 | 2006-09-20 | Rademaker Holding B V | Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, coumarine-group omvattende derivaten, een werkwijze voor de bereiding daarvan, en farmaceutische preparaten die deze bevatten. |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| CN101215258A (zh) * | 2008-01-21 | 2008-07-09 | 中国药科大学 | 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途 |
| JP5506788B2 (ja) | 2008-06-09 | 2014-05-28 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換４−（インダゾリル）−１，４−ジヒドロピリジン類およびそれらの使用方法 |
| EP2370070B9 (en) * | 2008-11-25 | 2014-04-23 | Boehringer Ingelheim Vetmedica GmbH | Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats. |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| GB201017783D0 (en) * | 2010-10-21 | 2010-12-01 | Shire Llc | Process for the preparation of anagrelide and analogues thereof |
| HUE060093T2 (hu) | 2012-03-15 | 2023-01-28 | Boehringer Ingelheim Vetmedica Gmbh | Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása |
| HUE054186T2 (hu) | 2013-07-19 | 2021-08-30 | Boehringer Ingelheim Vetmedica Gmbh | Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény |
| ES2883448T3 (es) | 2013-12-04 | 2021-12-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmacéuticas mejoradas de pimobendán |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN115838351B (zh) * | 2022-12-06 | 2025-01-28 | 昆明理工大学 | 4-烷基-1,4-二氢吡啶化合物及其制备方法和应用 |
| CN116693454A (zh) * | 2023-06-06 | 2023-09-05 | 中山大学 | 一种取代氰基喹啉酮类化合物及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57200386A (en) | 1981-06-04 | 1982-12-08 | Yoshitomi Pharmaceut Ind Ltd | Novel 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its salts |
| CH655110A5 (de) | 1982-09-03 | 1986-03-27 | Otsuka Pharma Co Ltd | Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten. |
| PT77842B (en) | 1982-12-21 | 1986-05-05 | Pfizer | Process for preparing dihydropyridines |
| GB8306666D0 (en) | 1983-03-10 | 1983-04-13 | Pfizer Ltd | Therapeutic agents |
| US4568677A (en) | 1983-07-23 | 1986-02-04 | Pfizer Inc. | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents |
| DE3445852A1 (de) * | 1984-12-15 | 1986-06-19 | Bayer Ag, 5090 Leverkusen | Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| GB8501395D0 (en) * | 1985-01-19 | 1985-02-20 | Pfizer Ltd | Dihydropyridine anti-ischaemic & anti-hypertensive agents |
| US4820842A (en) | 1986-11-19 | 1989-04-11 | Warner-Lambert Company | 2-substituted-1,4-dihydropyridines |
| US4723014A (en) | 1986-11-19 | 1988-02-02 | Warner-Lambert Company | Process for the preparation of 2-substituted-1,4-dihydropyridines |
| DE3712369A1 (de) * | 1987-04-11 | 1988-10-27 | Bayer Ag | Substituierte 5-nitro-1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung |
| DE3712371A1 (de) * | 1987-04-11 | 1988-10-27 | Bayer Ag | Substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung |
| DE3716652A1 (de) * | 1987-05-19 | 1988-12-08 | Bayer Ag | Dioxyalkylenaryl-dihydropyridine, zwischenprodukte zu ihrer herstellung, verfahren zu ihrer herstellung und ihre verwendung |
| DE3724909A1 (de) * | 1987-07-28 | 1989-02-09 | Bayer Ag | Neue substituierte nitro-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5096904A (en) | 1989-09-01 | 1992-03-17 | Glaxo Inc. | Pyridazinones having cardiotonic and beta blocking activities |
| WO1992006087A1 (en) * | 1990-10-02 | 1992-04-16 | Kaken Pharmaceutical Co., Ltd. | Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient |
| US5258519A (en) | 1990-11-13 | 1993-11-02 | Glaxo Inc. | Dihydropyridine vasodilators agents |
| US5100892A (en) * | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| CA2415899A1 (en) * | 2000-07-18 | 2003-01-13 | Chikashi Saitoh | Medicine comprising dicyanopyridine derivative |
| DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
-
2003
- 2003-10-07 CN CNA2003801052200A patent/CN1720243A/zh active Pending
- 2003-10-07 KR KR1020057005919A patent/KR20050070036A/ko not_active Withdrawn
- 2003-10-07 JP JP2004543386A patent/JP2006504738A/ja active Pending
- 2003-10-07 AU AU2003275450A patent/AU2003275450A1/en not_active Abandoned
- 2003-10-07 EP EP03759728A patent/EP1554267A1/en not_active Withdrawn
- 2003-10-07 BR BR0315103-4A patent/BR0315103A/pt not_active IP Right Cessation
- 2003-10-07 CA CA002501534A patent/CA2501534A1/en not_active Abandoned
- 2003-10-07 RU RU2005110062/04A patent/RU2005110062A/ru not_active Application Discontinuation
- 2003-10-07 PL PL03376405A patent/PL376405A1/xx not_active Application Discontinuation
- 2003-10-07 MX MXPA05003640A patent/MXPA05003640A/es unknown
- 2003-10-07 US US10/679,303 patent/US7098211B2/en not_active Expired - Fee Related
- 2003-10-07 WO PCT/US2003/031592 patent/WO2004033444A1/en not_active Ceased
-
2005
- 2005-04-04 ZA ZA200502711A patent/ZA200502711B/en unknown
- 2005-05-03 NO NO20052169A patent/NO20052169L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006504738A (ja) | 2006-02-09 |
| CN1720243A (zh) | 2006-01-11 |
| US20040242648A1 (en) | 2004-12-02 |
| WO2004033444A1 (en) | 2004-04-22 |
| ZA200502711B (en) | 2006-07-26 |
| PL376405A1 (en) | 2005-12-27 |
| US7098211B2 (en) | 2006-08-29 |
| EP1554267A1 (en) | 2005-07-20 |
| NO20052169L (no) | 2005-06-08 |
| MXPA05003640A (es) | 2005-11-17 |
| CA2501534A1 (en) | 2004-04-22 |
| BR0315103A (pt) | 2005-08-16 |
| AU2003275450A1 (en) | 2004-05-04 |
| KR20050070036A (ko) | 2005-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005110062A (ru) | Дигидропиридиновые соединения, обладающие одновременной способностью к блокированию кальциевых каналов l-типа и к ингибированию активности фосфодиэстеразы типа 3 | |
| RU2404979C2 (ru) | 2,4-ди(аминофенил)пиримидины в качестве ингибиторов рlk-киназ | |
| JP2004521097A5 (https=) | ||
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| RU2003122196A (ru) | Органические соединения | |
| RU2003117476A (ru) | Аминотиазолы и их применение в качестве антагонистов рецептора аденозина | |
| RU2006112593A (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk | |
| RU2003124076A (ru) | Фармацевтическая композиция, содержащая производные аминоацетонитрида, и ее применение в приготовлении фармацевтической композиции для обработки эндопаразитарных вредителей у животных | |
| NO170084C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive dihydropyridinderivater | |
| FR2562892A1 (fr) | Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes | |
| NO327709B1 (no) | 2'-substituerte 1,1'-bifenyl-2-karbonamider, deres anvendelse for fremstilling av et medikament sa vel som farmasoytiske preparater inneholdende disse | |
| RU2002116255A (ru) | Аминогетероцикламидные производные, обладающие пестицидной активностью | |
| DK333683D0 (da) | Fremgangsmade til fremstilling af 2-heteroaryl-alkoxymethyl-4-(aryl eller heteroaryl)-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller farmaceutisk acceptable syreadditionssalte deraf | |
| SI9210092B (en) | N-phenylcarbamate compound, procedure for its preparation and biocidal composition for pest control | |
| RU2004118247A (ru) | Бензимидазол-или индоламиноацетонитрильные производные для борьбы с паразитами | |
| HU191092B (en) | Process for producing 1,4-dihydro-pyridine derivatives | |
| RU2004114240A (ru) | Органические соединения | |
| RU2004139033A (ru) | Индазоламиноацетонитрильные производные, обладающие особой пестицидной активностью | |
| RU2004120790A (ru) | Аминоацетонитрильные производные и их применение для борьбы с паразитами | |
| RU2008127257A (ru) | Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов | |
| RU2372348C2 (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
| RU2003127748A (ru) | Производные 4-аминобензопирана | |
| US4414213A (en) | Dihydropyridyl cyclic imidate esters and their pharmaceutical use | |
| Şimşek et al. | Synthesis and calcium antagonistic activity of 2, 6, 6-trimethyl-3-carbomethoxy (ethoxy)-4-aryl-1, 4, 5, 6, 7, 8-hexahydroquinoline derivatives | |
| CA1255660A (en) | Tetrahydrothienopyridines, a process for their preparation and their use as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20071004 |